title: Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia.
authors: Nadav
authors: N
authors: Sarid
authors: Rinat
authors: R
authors: Eshel
authors: Rachel
authors: R
authors: Rothman
authors: Meirav
authors: M
authors: Shpringer
authors: Chava
authors: C
authors: Perry
authors: Irit
authors: I
authors: Solar
authors: Nili
authors: N
authors: Dezorella
authors: Lili
authors: L
authors: Gepstein
authors: Jonathan
authors: J
authors: Canaani
authors: Elizabeth
authors: E
authors: Naparstek
authors: Aaron
authors: A
authors: Polliack
authors: Yair
authors: Y
authors: Herishanu
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001483:Base Sequence; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D015342:DNA Probes / Q000235:genetics; D015321:Gene Rearrangement; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000209:etiology* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000235:genetics*; D000069283:Rituximab; D014178:Translocation, Genetic; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D015342:DNA Probes; C497422:KMT2A protein, human; D051788:Myeloid-Lymphoid Leukemia Protein; D000069283:Rituximab; D003520:Cyclophosphamide; D011495:Histone-Lysine N-Methyltransferase; D014740:Vidarabine; C024352:fludarabine